Prestige BioPharma aims to expand its drug pipeline with a $152 million research and development facility.
Prestige BioPharma, a Singapore-based company that has a trastuzumab biosimilar (HD201) under regulatory review, said it will build a $152 million research and development facility measuring 45,000 square meters in Busan, Republic of Korea.
The company recently signed a memorandum of understanding with the Busan City government, which in this project is celebrating the construction of its first biopharmaceutical center. Prestige said it would staff the facility over the next 5 years with 209 workers with PhDs and research and development skills.
HD201 recently completed a phase 3 clinical trial and is under review for approval by the European Medicines Agency (EMA). The Prestige pipeline also includes bevacizumab (HD204) and adalimumab (PBP1502) biosimilar candidates. HD204 is in phase 3 development, and the adalimumab candidate is in phase 1.
In addition, Prestige has a first-in-class antibody (PBP1510) under development for pancreatic cancer that targets pancreatic adenocarcinoma upregulated factor. The drug has received orphan designations from the FDA, the EMA, and the Korean Ministry of Food and Drug Safety. These designations streamline the development and review processes that precede marketing approval.
Prestige has also begun a venture into vaccine development and production and participated in the production of Russia’s Sputnik 5 COVID-19 vaccine.
“Prestige BioPharma will be able to accelerate the development of innovative antibody drugs and at the same time contribute to the growing global demands of vaccines in response to COVID-19 and potential future pandemics,” said Lisa S. Park, CEO, in a statement.
In April 2021, Prestige announced an agreement with Pharmapark, of Moscow, Russia, for the distribution of Prestige’s HD204 in Russia. The monoclonal antibody inhibits the growth of tumors and is useful in the treatment of multiple forms of cancer, including colorectal cancer, non–small cell lung cancer, and kidney cancer, among others.
For more about Prestige BioPharma's growth strategy, click here.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Health Canada Approves First Omalizumab Biosimilar
December 16th 2024Health Canada has approved Omlyclo, the first omalizumab biosimilar in Canada, for the treatment of chronic idiopathic urticaria, allergic asthma, and chronic rhinosinusitis with nasal polyps, based on a phase 3 study confirming its bioequivalence to the reference product.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Review Confirms Clinical Safety of Sandoz Denosumab Biosimilar vs Originator
December 11th 2024Sandoz's biosimilar denosumab (Jubbonti/Wyost) has demonstrated analytical, pharmacokinetic, pharmacodynamic, and clinical equivalence to reference denosumab (Prolia/Xgeva), supporting its approval and extrapolation to all approved indications.
Eye on Pharma: Golimumab Biosimilar Update; Korea Approves Denosumab; Xbrane, Intas Collaboration
December 10th 2024Alvotech and Advanz Pharma have submitted a European marketing application for their golimumab biosimilar to treat inflammatory diseases, while Celltrion secured Korean approval for denosumab biosimilars, and Intas Pharmaceuticals partnered with Xbrane Biopharma on a nivolumab biosimilar.